High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
We just covered the 10 Best Stocks to Buy Right Now According to AI and Eli Lilly and Company (NYSE:LLY) ranks 4th on this list. Eli Lilly and Company (NYSE:LLY) is a premier global pharmaceutical corporation dedicated to discovering, developing, and manufacturing innovative human medicines across multiple therapeutic areas. The company’s primary growth catalyst is […]
Lilly shares soared more than 18% in May.
Hanmi will receive $75m upfront and may earn up to $1.185bn in milestone payments for development and approvals.
Eli Lilly and Company (NYSE:LLY) announced positive data from its Phase 3 LIBRETTO-432 trial, showing that Retevmo significantly lowered the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC) following initial treatment. The study found that treatment with Retevmo (selpercatinib) reduced the risk of recurrence or death by 83% compared with placebo, highlighting the drug’s potential role as an adjuvant therapy for patients with
Eli Lilly (LLY) and Company announced results from the Phase 3 Libretto-432 clinical trial of Retevmo as adjuvant therapy versus placebo in patients with early-stage rearranged during transfection fusion-positive non-small cell lung cancer, NSCLC. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival with selpercatinib reducing the risk of disease recurrence or death by 83% versus pl
Recent performance context for Eli Lilly (LLY) Eli Lilly (LLY) has drawn investor attention after a period where the stock rose about 15% over the past month and about 10% over the past 3 months, alongside strong reported revenue and net income figures. See our latest analysis for Eli Lilly. That recent 14.7% 30 day share price return comes on top of a 48.9% total shareholder return over the past year and a very large 5 year total shareholder return, so momentum has been building over both...
Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.
Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...
Eli Lilly and Company (NYSE:LLY) is one of the top long-term stocks to buy. On May 25, Eli Lilly and Company (NYSE:LLY) delivered positive Phase 1b Heart-2 study results for VERVE-102, an investigational base-editing therapy designed to deactivate the PCSK9 gene in the liver. The trial results show that VERVE-102 successfully reduced PCSK9 by up […]
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.
CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS Caremark's GLP-1 obesity drug coverage. The change affects access and competitive positioning for GLP-1 obesity therapies in CVS Caremark's network. Novo Nordisk, listed as CPSE:NOVO B, is a key player in GLP-1 based therapies, with Wegovy at the center of its obesity drug portfolio. CVS Caremark's move...
Lilly has split its stock in the past.
United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
The stock market hit fresh highs on Iran deal hopes. Nvidia, Tesla lead five trillion-dollar titans near buy points.
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
Eli Lilly is near an all-time high in Friday's stock market after a strong first-quarter report. Shares are below a 1133.95 pivot.
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented: Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, […]
Eli Lilly's $1 trillion comeback is powered by the company's experimental next-generation obesity drug, Reta.
Eli Lilly and Company (NYSE:LLY) is one of the 12 Most Profitable Stocks to Invest In. On May 25, 2026, Eli Lilly and Company (NYSE:LLY) announced positive Phase 1b Heart-2 study results for Verve-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood […]
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
The change could improve patient access and support future sales growth.
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
